Skip to main content

Table 5 Cumulative percentages of children with recrudescent infections during follow-up in the two treatment groups

From: Paracetamol versus placebo in treatment of non-severe malaria in children in Guinea-Bissau: a randomized controlled trial

 

Paracetamol

Placebo

OR with confidence interval*

OR with confidence interval**

ETF

1.2% (2/167)

4.1% (7/171)

0.28 (0.03 - 1.53)

 

Day 4 - 7

4.3% (6/161)

9.5% (9/161)

0.49 (0.18 - 1.24)

0.88 (0.25 - 2.86)

Day 8 - 14

12.2% (12/144)

12.1% (4/135)

0.98 (0.49 - 1.95)

1.36 (0.62 - 3.08)

Day 15 -21

16.6% (6/121)

14.3% (3/120)

1.12 (0.60 - 2.07)

1.49 (0.74 - 3.04)

Day 22 - 28

17.4% (1/109)

14.3% (0/111)

1.16 (0.63 - 2.15)

1.55 (0.78 - 3.16)

Day 29 - 35

17.4% (0/97)

14.3% (0/103)

1.16 (0.63 - 2.15)

1.55 (0.78 - 3.16)

  1. Cumulative percentages of children with recrudescent infections during follow-up. The number of children with recrudescent infections/total number of children is given in parenthesis.
  2. *) The OR (with confidence intervals in brackets) of having recrudescent infections in the paracetamol group as compared to the placebo group when recrudescent infections are defined as PCR-proven recrudescent infections plus ETF.
  3. **) The OR (with confidence intervals in brackets) of having recrudescent infections in the paracetamol group as compared to the placebo group when recrudescent infections are defined as PCR-proven recrudescent infections.
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us